Durvalumab is an anti-PD-L1 monoclonal antibody, humanized.Durvalumab completely blocked the binding of PD-L1 to PD-1 and CD80, and the IC50s were 0.1 and 0.04 nM, respectively.

Durvalumab inhibits tumor growth in a mouse xenograft model of human melanoma (A375) and pancreatic (HPAC) tumor cell lines through a T-cell-mediated mechanism.The tumor growth inhibition of HPAC cells was 74% and that of A375 cells was 77%.Durvalumab had no effect on the growth of the A375 xenograft tumor in the absence of T cells.

1428935-60-7

德瓦鲁单抗;MEDI 4736